Heart Tumor Market Analysis

Tumor Type (Primary Tumors and Secondary Tumors)

Primary tumor segment is estimated to hold heart tumor market share of over 81% by the end of 2037. Primary cardiac tumors often require critical imaging and diagnosis for the purpose of treatment. In October 2022, Siemens Healthineers launched a budget-friendly MRI scanner to increase the accessibility of magnetic resonance imaging. The progress made in this area supports the increased demand for diagnostic tests of the primary tumor, as accessible solutions to these tests are offered to healthcare providers.

Treatment (CT Scan, MRI Scan, Nuclear Imaging, Echocardiography)

In heart tumor market, echocardiography segment is set to account for revenue share of more than 51% by the end of 2037, facilitated by the modality's capability for the non-invasive detection of heart tumors. Echocardiography remains a cornerstone in cardiac tumor diagnostics due to its broad accessibility and affordability as a diagnostic modality. In June 2024, Cleerly introduced Cleerly ISCHEMIA, a diagnostic based on coronary computed tomography angiography, underlining the value of imaging tools in cardiac diagnostics. This growing preference for echocardiography underlines its relevance in the market because it is affordable and robust in diagnostic accuracy.

Our in-depth analysis of the market includes the following segments